ArticleBMC infectious diseases2026
Emergence of NDM-type metallo-β-lactamase and ArmA 16S rRNA methylase co-producing Morganella morganii in Myanmar.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundMorganella morganii is intrinsically resistant to a wide range of antibiotics and is increasingly being reported worldwide.
methodsA total of five M. morganii isolates were obtained from five patients at three hospitals in Myanmar between Sept. 2023 and Oct. 2024. Minimum inhibitory concentrations (MICs) were determined using the broth microdilution method. Genomic DNA was extracted and sequenced on the next generation sequencer. Drug-resistant factors were determined and the genetic environments surrounding carbapenemase and 16S rRNA methylase genes were analyzed. A phylogenetic tree was constructed using forty-six M. morganii subsp. morganii genome sequences, including the five isolates from Myanmar.
resultsOne isolate harbored both blaNDM−1 and armA. This isolate was resistant to imipenem (MIC: 16 µg/ml) but susceptible to meropenem (MIC: 1 µg/ml). Whole genome sequencing revealed that blaNDM−1 and armA were located in close proximity on the chromosome of M. morganii strain YGH122, with the genetic region flanked by the two IS26 elements. Twenty-four strains deposited in GenBank carry the identical IS26-flanked genetic structure.
conclusionsThis is the first report of a clinical M. morganii isolate co-harboring blaNDM−1 and armA in Myanmar. These genes located on chromosome with the genetic region flanked by the two IS26 elements. The presence of this structure suggests the possibility of horizontal co-transfer of these resistance genes from other Enterobacterales, such as Escherichia coli and Klebsiella pneumoniae.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.